Mithra Pharmaceuticals S.A.
MITPF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $40 | $67 | $23 | $9 |
| % Growth | -40.1% | 195.6% | 151% | – |
| Cost of Goods Sold | $34 | $32 | $26 | $13 |
| Gross Profit | $6 | $35 | -$3 | -$4 |
| % Margin | 14.9% | 52.9% | -15.4% | -47.6% |
| R&D Expenses | $63 | $64 | $85 | $78 |
| G&A Expenses | $22 | $15 | $13 | $16 |
| SG&A Expenses | $12 | $17 | $14 | $17 |
| Sales & Mktg Exp. | $2 | $2 | $2 | $1 |
| Other Operating Expenses | $0 | $28 | -$0 | -$0 |
| Operating Expenses | $75 | $69 | $89 | $86 |
| Operating Income | -$69 | -$33 | -$93 | -$90 |
| % Margin | -172.6% | -49.9% | -408.9% | -999.5% |
| Other Income/Exp. Net | -$92 | $20 | -$38 | -$23 |
| Pre-Tax Income | -$162 | -$14 | -$126 | -$113 |
| Tax Expense | $12 | $46 | -$9 | -$21 |
| Net Income | -$174 | -$60 | -$117 | -$92 |
| % Margin | -432.1% | -89% | -515.6% | -1,019.8% |
| EPS | -2.51 | -1.22 | -2.69 | -2.25 |
| % Growth | -105.7% | 54.6% | -19.6% | – |
| EPS Diluted | -2.51 | -1.22 | -2.69 | -2.25 |
| Weighted Avg Shares Out | 69 | 49 | 43 | 41 |
| Weighted Avg Shares Out Dil | 69 | 49 | 43 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $14 | $12 | $4 |
| Interest Expense | $23 | $17 | $12 | $4 |
| Depreciation & Amortization | $12 | $12 | -$8 | -$9 |
| EBITDA | -$53 | $17 | -$82 | -$80 |
| % Margin | -131.4% | 26.1% | -362.9% | -890.1% |